Impact of detrusor underactivity on the postoperative outcomes after benign prostatic enlargement surgery.


Journal

Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326

Informations de publication

Date de publication:
03 2021
Historique:
revised: 06 10 2020
received: 22 08 2020
accepted: 04 01 2021
pubmed: 2 3 2021
medline: 12 6 2021
entrez: 1 3 2021
Statut: ppublish

Résumé

Previous studies suggest that men with detrusor underactivity (DUA) have less symptomatic improvement after prostate surgery than those with normal contractility, but the available data is controversial. We aim to determine the differences in functional outcomes of patients with or without DUA who underwent photovaporization of the prostate (PVP) with GreenLight™180 W XPS. A cohort of patients with lower urinary tract symptoms (LUTS) who underwent PVP between 2012 and 2019 was evaluated. Patients were stratified according to bladder contractility index (BCI). DUA was defined as BCI < 100. Those with normal contractility (BCI = 100-150) were included in Group 1, and those with DUA (BCI < 100) in Group 2. Primary outcomes were symptomatic improvement defined as a reduction ≥ 4 points in the international prostate symptom score (IPSS) and a reduction of at least 1 point in the quality of life (IPSS-QoL). Complications according to the Clavien-Dindo classification were also recorded. A total of 271 patients who underwent PVP with GreenLight™ and met the inclusion criteria were assessed. Group 1 included 158 patients, while Group 2 included 113 patients. Mean follow-up was 24 months. Patients with normal contractility had a median reduction of 11 points (18.9 ± 8.0 to 7.1 ± 7.0) while patients with DUA had a median reduction of 10 points (19.3 ± 6.9 to 8.6 ± 8.4) in IPSS score; these differences were not statistically significant (p = .20). Patients in Group 1 had a 1.92 higher chance of QoL improvement (OR, 1.92; 90% CI, 1.10-3.37), compared to those in Group 2. Failure to void after PVP was most frequently reported in DUA patients (OR, 2.36; 90% CI, 1.26-4.43). Sociodemographic characteristics, intraoperative complications, conversion rates, hospital stay, and urinary catheterization time were similar between groups. Patients with LUTS, regardless of their BCI, improved their symptoms after PVP according to the IPSS. However, patients with DUA were more likely not to improve their QoL after the procedure and had a higher chance of failure to void in the immediate postoperative period. An appropriate counseling process with the patient discussing possible outcomes based on these findings should be encouraged.

Identifiants

pubmed: 33645847
doi: 10.1002/nau.24637
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

868-875

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

D'Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433-477. https://doi.org/10.1002/nau.23897
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178. https://doi.org/10.1002/nau.10052
Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099-1109. https://doi.org/10.1016/j.eururo.2014.12.038
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
Osman NI, Esperto F, Chapple CR. Detrusor underactivity and the underactive bladder: a systematic review of preclinical and clinical studies. Eur Urol. 2018;74(5):633-643. https://doi.org/10.1016/j.eururo.2018.07.037
Kim M, Jeong CW, Oh S-J. Effect of preoperative urodynamic detrusor underactivity on transurethral surgery for benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol. 2018;199(1):237-244. https://doi.org/10.1016/j.juro.2017.07.079
Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53(5):342. https://doi.org/10.4111/kju.2012.53.5.342
Kim DK. Current pharmacological and surgical treatment of underactive bladder. Investig Clin Urol. 2017;58(suppl 2):S90. https://doi.org/10.4111/icu.2017.58.S2.S90
Yu Z, Li J, Li Z, Hou R. Photoselective vaporization of the prostate and simultaneous suprapubic cystostomy for the treatment of benign prostatic hyperplasia in patients with mild to severe detrusor underactivity. Urol Int. 2015;95(3):269-275. https://doi.org/10.1159/000434688
Osman NI, Chapple CR, Abrams P, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65(2):389-398. https://doi.org/10.1016/j.eururo.2013.10.015
Blanker MH, Alma HJ, Devji TS, Roelofs M, Steffens MG, van der Worp H. Determining the minimal important differences in the International Prostate Symptom Score and Overactive Bladder Questionnaire: results from an observational cohort study in Dutch primary care. BMJ Open. 2019;9(12):e032795. https://doi.org/10.1136/bmjopen-2019-032795
Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients? J Urol. 1995;154(5):1770-1774. https://doi.org/10.1016/S0022-5347(01)66780-6
Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518-526. http://www.ncbi.nlm.nih.gov/pubmed/1598671
Foster H, Barry M, Gandhi M, et al. Benign prostatic hyperplasia: surgical management of benign prostatic hyperplasia/lower urinary tract symptoms (2018, amended 2019). Clinical Guidelines of the American Urological Association. January 2019:1-42.
Gravas S, Cornu JN, Gacci M, et al. EAU Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS). Eur Assoc Urol. 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#9
Robertson AS, Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. J Urol. 1996;155(2):506-511. http://www.ncbi.nlm.nih.gov/pubmed/8558647
Drake MJ, Lewis AL, Young GJ, et al. Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: a noninferiority randomised controlled trial of urodynamics in 26 hospitals. Eur Urol. 2020;78:701-710. https://doi.org/10.1016/j.eururo.2020.06.004
Thomas D, Zorn KC, Zaidi N, et al. Does urodynamics predict voiding after benign prostatic hyperplasia surgery in patients with detrusor underactivity? Asian J Urol. 2019;6(3):264-269. https://doi.org/10.1016/j.ajur.2018.12.005
Tanaka Y, Masumori N, Itoh N, Furuya S, Ogura H, Tsukamoto T. Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity? Int J Urol. 2006;13(11):1398-1404. https://doi.org/10.1111/j.1442-2042.2006.01589.x
Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int. 2009;105(10):1429-1433. https://doi.org/10.1111/j.1464-410X.2009.08978.x
Cho MC, Ha SB, Park J. Impact of detrusor underactivity on surgical outcomes of laser prostatectomy: comparison in serial 12-month follow-up outcomes between potassium-titanyl-phosphate photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prost. Urology. 2016;91:158-166. https://doi.org/10.1016/j.urology.2015.11.052
Choi SW, Choi YS, Bae WJ, et al. 120 W greenlight HPS laser photoselective vaporization of the prostate for treatment of benign prostatic hyperplasia in men with detrusor underactivity. Korean J Urol. 2011;52(12):824. https://doi.org/10.4111/kju.2011.52.12.824
Cho MC, Park J, Kim JK, et al. Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? A serial 3-year follow-up study. Neurourol Urodyn. 2018;37(1):407-416. https://doi.org/10.1002/nau.23317
Paick J-S, Um JM, Kwak C, Kim SW, Ku JH. Influence of bladder contractility on short-term outcomes of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate. Urology. 2007;69(5):859-863. https://doi.org/10.1016/j.urology.2007.01.042
Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE. Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology. 2014;83(2):428-432. https://doi.org/10.1016/j.urology.2013.09.035
Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. Urology. 2016;97:208-211. https://doi.org/10.1016/j.urology.2016.07.010
Cho MC, Yoo S, Park J, et al. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data. BJU Int. 2019;123(5A):E34-E42. https://doi.org/10.1111/bju.14661

Auteurs

Mauricio Plata (M)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Jessica Santander (J)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Carlos Gustavo Trujillo (CG)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Alejandra Bravo-Balado (A)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Daniela Robledo (D)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Tatiana Higuera (T)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Juan Ignacio Caicedo (JI)

Department of Urology, Hospital Universitario Fundación Santa Fe de Bogotá and Universidad de los Andes School of Medicine, Bogotá, Distrito Capital, Colombia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH